With Cell and Gene Therapies Proliferation, Specialty Pharmacy Faces New Pricing, Distribution Pressures

Key Takeaways

• Cell and gene therapies could cost $150 billion for 50k patients.
• Specialty pharmacies must redesign pricing, contracting, and risk models.
• Two distribution models: flash‑title (manufacturer risk) and drive‑by (pharmacy risk).
• Manufacturers increasingly shift from buy‑and‑bill to specialty‑pharmacy partnerships.
• Orsini leverages 30‑year medical‑benefit expertise to manage gene‑therapy risk.

Pulse Analysis

The pipeline of cell and gene therapies is expanding at an unprecedented pace, with the FDA having approved roughly 50 products and dozens more in late‑stage trials. Hematologic cancers, neurology, retinal disorders, and emerging cardiac indications are driving demand, pushing these once‑ultra‑rare treatments into larger patient cohorts. At an estimated $3 million per dose, even modest adoption rates translate into multi‑hundred‑billion‑dollar spend, reshaping the overall U.S. pharmaceutical market and prompting stakeholders to reassess value frameworks.

Traditional distribution models—flash‑title, where manufacturers retain risk until delivery, and buy‑and‑bill, where treatment centers purchase and bill payers—were designed for low‑volume, high‑cost drugs. As therapy volumes climb, those models strain under inventory, logistics, and cash‑flow pressures. Specialty pharmacies are emerging as hybrid intermediaries, adopting the “drive‑by” approach that transfers financial exposure and inventory management to the pharmacy while still coordinating patient access. Companies like Orsini illustrate this evolution, leveraging three decades of medical‑benefit expertise to navigate complex payer contracts and assume risk for $3 million gene‑therapy transactions.

The pricing playbook must also evolve. Payers will need to compare these curative‑potential therapies against established standards of care, demanding new outcome‑based contracts and amortized payment structures. Manufacturers are already courting specialty pharmacies to offload risk and improve market access, signaling a broader industry shift toward integrated supply‑chain solutions. As outpatient administration grows, the convergence of pharmacy benefit and medical benefit expertise will be critical to ensuring that high‑cost, high‑impact therapies reach patients without destabilizing the broader healthcare economy.